Literature DB >> 25824520

Anticoagulation therapy. Optimal dosages and genotypes for edoxaban therapy.

Karina Huynh.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25824520     DOI: 10.1038/nrcardio.2015.44

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  2 in total

1.  Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Authors:  Jessica L Mega; Joseph R Walker; Christian T Ruff; Alexander G Vandell; Francesco Nordio; Naveen Deenadayalu; Sabina A Murphy; James Lee; Michele F Mercuri; Robert P Giugliano; Elliott M Antman; Eugene Braunwald; Marc S Sabatine
Journal:  Lancet       Date:  2015-03-11       Impact factor: 79.321

2.  Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Authors:  Christian T Ruff; Robert P Giugliano; Eugene Braunwald; David A Morrow; Sabina A Murphy; Julia F Kuder; Naveen Deenadayalu; Petr Jarolim; Joshua Betcher; Minggao Shi; Karen Brown; Indravadan Patel; Michele Mercuri; Elliott M Antman
Journal:  Lancet       Date:  2015-03-11       Impact factor: 79.321

  2 in total
  1 in total

Review 1.  Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.

Authors:  Natalia Cullell; Caty Carrera; Elena Muiño; Nuria Torres; Jerzy Krupinski; Israel Fernandez-Cadenas
Journal:  Oncotarget       Date:  2018-06-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.